Botanix’s hyperhidrosis treatment Sofdra gains FDA approval
20 Jun 2024
Clinical ResultPhase 3Drug Approval
Preview
Source: Pharmaceutical Technology
The treatment is indicated for usage in adults and children aged nine years and above. Credit: BongkarnGraphic / Shutterstock.
Botanix Pharmaceuticals has announced the receipt of approval from the US Food and Drug Administration (FDA) for Sofdra (sofpironium) gel, 12.45%, for excessive underarm sweating (primary axillary hyperhidrosis).
The treatment is indicated for usage in adults and children aged nine years and above.
Sofdra is the first and only new chemical entity to receive approval in the US for this condition.
The FDA’s decision was based on the results from the two Phase III CARDIGAN studies in 701 patients.
The trials assessed the efficacy and safety of Sofdra versus vehicle in primary axillary hyperhidrosis patients.
See Also:SGNB-7H4V by Pfizer for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast CancerHER2- Breast Cancer): Likelihood of Approval
Preview
Source: Pharmaceutical Technology
SGNB-7H4V by Pfizer for Epithelial Ovarian Cancer: Likelihood of Approval
Preview
Source: Pharmaceutical Technology
Sofdra met all primary and secondary endpoints, demonstrating significant changes from baseline in Gravimetric Sweat Production (GSP) and the Hyperhidrosis Disease Severity Measure-Axillary, 7-item (HDSM-AX7) score.
Botanix will commence an early patient experience programme in the third quarter (Q3) of 2024, allowing qualified patients to obtain early access to Sofdra.
This programme will support patients through telemedicine and the payer reimbursement process, making them the first to use Sofdra commercially.
A broader launch is anticipated in early Q4 2024.
“This is a transformative event for Botanix as we transition from a development stage to a revenue-generating dermatology company.”
Botanix executive chairman Vince Ippolito stated: “We are very excited to provide a new option for the 10 million patients with primary axillary hyperhidrosis in the United States.”
“As the first and only new chemical entity, Sofdra represents a new therapeutic approach for dermatologists to treat patients with this disabling medical condition.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.